Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

102.06
Delayed Data
As of Sep 04
 +0.15 / +0.15%
Today’s Change
85.95
Today|||52-Week Range
123.37
+8.27%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$149.6B

Company Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its primary areas of focus include primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Contact Information

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City California 94404
P:(650) 574-3000
Investor Relations:
(650) 522-1936

Employees

Shareholders

Mutual fund holders46.66%
Other institutional37.42%
Individual stakeholders1.06%

Top Executives

John C. MartinChairman & Chief Executive Officer
John F. MilliganPresident & Chief Operating Officer
Robin L. WashingtonChief Financial Officer & Executive Vice President
Norbert W. BischofbergerChief Scientific Officer & Executive VP-Research
William A. LeeExecutive Vice President-Research